Author Archives: admin


Sustainably Yours: The importance of understanding and trusting in Science – The Phuket News

In his book 21 Lessons for The 21st Century, historian Yuval Noah Harari begins by writing, In a world deluged by irrelevant information, clarity is power. Before the Internet, access to information was relatively limited, and media was concentrated in the hands of a few corporations, which had its problems.

When it comes to supposed facts about COVID-19 posted on the internet, its best to check first with those doing the real checking: scientists. Photo: AFP

Today, with YouTubers, bloggers, and social media at our fingertips, the world is filled with more information than ever. The problem is that much of it is fake news and rumours. Too many voices are clamouring for our attention, but few are fact-checked for accuracy.

Since the spread of COVID-19 began, weve seen snake oil salesmen hawking cures and prophylaxis, and the spread of conspiracy theories about the viruss origins.

In a world where breathing the same air as someone else can kill you, misinformation can be as deadly as the virus. Now more than ever we need to be mindful of what we say, what we post, and how we behave. So, we need to understand and trust in science.

Why Should We Believe in Science?

According to Harvard Professor Naomi Oreskes, author of Why Trust Science?, for several decades there has been an organised campaign to undermine the publics trust in science funded mainly by industries whose financial interests are threatened by its findings.

At its core, science is the study of how the natural world works.

It has a long history of success, and when done correctly it is the single best method of inquiry we have for the pursuit of truth. Because of science, we have aeroplanes, cars, GPS, the Internet, smartphones and modern medicine. The only reason we know that COVID-19 exists is because of science. More importantly, science is a self-policing system of checks and balances that exists to reveal problems and correct inaccuracies.

It begins with the scientific method, something we all learned in school:

Once a scientist has drawn a conclusion, it undergoes rigorous scrutiny by colleagues who are working in the same discipline. This process of scrutiny can lead to rejecting or accepting the hypothesis, redesigning the experiment or finding additional data to support the conclusion. If the claim is valid, the scientist then publishes their work in a reputable scientific journal such as Nature or Science.

Submission of a paper begins the rigorous peer-review process where experts in the same field deliberately challenge the scientists arguments, inspect their data and look for errors in their methodology. So, before a claim is made and the general media gets a hold of it, a study is peer-reviewed and subjected to scrutiny by dozens, if not hundreds of other experts in the same field.

In areas where there is a scientific consensus, such as the relative safety and efficacy of vaccines, or that climate change is anthropogenic, thousands of studies on these topics have been published over decades and reviewed by thousands of scientists in dozens of countries.

Professor Oreskes notes that a critical aspect of scientific judgment is that it is done collectively and not individually. This weeds out personal biases or someone who might have a specific agenda.

Scientific claims are put through a process much like a trial. Questions are posed, data is analysed, and facts are debated before the community comes to a consensus. This process can take years, even decades. So, when your beliefs are founded on scientific consensus, you are relying on the knowledge of dozens if not hundreds, or thousands of experts in their fields.

Because COVID-19 is still so new, there are lots of unknowns. It will take time to review the data and draw definitive conclusions. There remains speculation about how the virus transmits, whether recovered patients acquire sustained immunity, the effect of heat and humidity have on infection rates and the viability of various treatments, among other things. Nevertheless, our reaction to COVID-19 should be grounded in facts, evidence and empirical data rather than, unfounded opinions, suppositions and fears.

Science Makes Mistakes

Like any other human discipline, science has its failures. For example, in 2014, Japanese biologist Haruko Obokata knowingly falsified data regarding the creation of stimulus acquired pluripotent (STAP) cells in mice. If her claim had been valid, it would have revolutionised the production of embryonic stem cells, which are blank cells that can be programmed to become any of 200 different cell types in the human body, including bone, hair, skin or muscle.

However, due to the self-policing nature of science, within days, other biologists in her field refuted her claims after failing to replicate her experiments. Within months, her paper was retracted, and her career ended in disgrace.

Knowing that science sometimes makes mistakes and admits and corrects for them shouldnt make us trust it any less if anything it should make us believe in it more. Especially when compared to other methods of inquiry, which have no process of scrutiny.

The Problem with Intuition

In his book Thinking Fast Thinking Slow, Nobel Prize-winning behavioural economist Daniel Kahneman defined intuition as, Thinking that you know something without knowing why you do. As an example, he poses this problem:

A bat and ball cost $1.10.

The bat costs one dollar more than the ball.

How much does the ball cost?

If you answered 10 cents, you are incorrect. This question confounds 50% of students from some of the best universities in the world.

The correct answer is 5 cents.

Kahneman identifies two methods for problem-solving. System 1 is quick, intuitive, spontaneous and effortless. It instantly helps us to recognise faces, to act when confronted with dangers and to solve simple questions. System 2 is slow, rational, reflective and effortful. It gets into the drivers seat when you focus and concentrate on a complicated problem.

The problems occur when we try to use System 1 to make complex decisions that require System 2. People will often make judgements based on intuition when a given situation is easy to imagine. For example, when asked what the most dangerous method of generating energy is, public opinion is usually most negative toward nuclear. However, on a per terawatt-hour basis, atomic energy has killed far fewer people than oil, coal and even solar. But because most people conflate nuclear power with war, they tend to answer incorrectly.

When our perception of reality is based on stories that people tell us, rather than science, facts and evidence, it leads to poor decisions. In the modern world, we need to learn to think in terms of data as it is a far too complicated a place to always reason by intuition.

Linear Vs. Exponential Thinking

Part of the reason many governments didnt foresee the problems COVID-19 would create is that their leaders are linear thinkers.

As an example, if you take 30 linear steps, you move 30 standard paces from where you started, or about 30 metres. However, if you take 30 exponential steps, one, two, four, eight, sixteen by the time you get to the last step, you end up a billion metres from where your started thats about 26 times around the planet!

Its the reason why at the beginning of March the United States only had 65 infections and by April 14 it had over 500,000.

We are In This Together

Whether we like it or not, we are in this together. The virus doesnt distinguish between race, social class, tourist, expat or Thai.

We must be careful about what we say or post in social media. The virus kills quickly, but misinformation can also kill by influencing people to do foolish things.

For sources of science that have been peer-reviewed or vetted by experts, you can go to the following websites:

PubMed

The Lancet

Nature Medicine

The New England Journal Of Medicine

The British Medical Journal

WebMD

Healthline

When we depend on intuition, gossip, fake news and conspiracy theories to make decisions, we get leaders who make demonstrably poor decisions that lead to disastrous consequences. In this regard many people think of Donald Trump.

To quote John F. Kennedy, We are not here to curse the darkness, but to light the candle that can guide us through that darkness to a safe and sane future.

Science, both literally and figuratively, is that light; to disregard it is to remain in the dark.

Follow this link:
Sustainably Yours: The importance of understanding and trusting in Science - The Phuket News

Stem cell therapy shows 83% survival of Coronavirus patients on ventilators – International Business Times, Singapore Edition

Top US vaccine expert was fired

Patients with acute respiratory distress syndrome (ARDS), a symptom of COVID-19, received a stem cell therapy which resulted in an 83 percent survival rate in ventilator-dependent coronavirus patients with moderate to severe ARDS

The drugs given were two intravenous infusions of the experimental 'allogeneic mesenchymal stem cell' candidate Ryoncil (remestemcel-L) by Mesoblast Limited based in Australia and the United States. Ryoncil, under a priority review by the FDA, is also under development for other rare diseases and inflammatory conditions, according to the company's release.

The company had previously announced that the drug received clearance from the US Food and Drug Administration (FDA) earlier this month as an Investigational New Drug (IND) to treat those with ARDS caused by novel coronavirus infection under expanded access compassionate use and also in a planned randomized controlled trial.

Among the 12 patients, nine were off ventilators within 10 days. There was 83 percent survival rate. Seven patients were already discharged. However, all the patients also received other experimental therapies before receiving the stem cell one, at New York City's Mt Sinai hospital.

Once ventilated after facing acute respiratory distress syndrome, the likelihood of coming off the ventilator is nine percent, while the survival rate is 12 percent, said Mesoblast CEO Silviu Itescu to BioWorld. The company would complete the phase II/III trials which are randomized placebo-controlled ones to confirm the efficiency of remestemcel-L

The drug focuses on rare adult stem cells called MLC's that responds to signals that are linked to tissue damage, and secrete molecules promoting tissue repair and also modulates immune responses. The drug is believed to counter the inflammatory processes by decreasing the production of pro-inflammatory cytokines while increasing the production of anti-inflammatory cytokines that stops the inflammations caused by the coronavirus.

This comes at a time when hydroxychloroquine, the most hopefully talked about drug failed in tests. Even Gilead's remdesivir, which even the WHO upheld, failed in the first randomized controlled trial. It is to be seen how stem cell therapy works out.

See original here:
Stem cell therapy shows 83% survival of Coronavirus patients on ventilators - International Business Times, Singapore Edition

There’s no treatment for COVID-19, but Virginia researchers are ramping up clinical trials to try to find one – Richmond.com

For the doctors treating the hundreds of patients who are hospitalized for COVID-19 in Virginia, there's no playbook. The disease that has spread rapidly across the world - killing hundreds in the state and more than 200,00 worldwide - has no known treatment, so COVID-19 has presented a unique challenge to the doctors faced with saving lives against a mostly-unknown enemy.

But, in an effort to discover treatments, medical researchers in the state have dropped everything to ramp up experimental clinical trials that many be the patients' best hope of recovery.

When Dr. Antonio Abbate, speaks with patients about the possibility of joining a clinical trial, hes used to standing next to the patients, holding their hands and looking into their eyes.

Joining a clinical trial means he or she is volunteering to receive an experimental treatment that has not been proven to be effective. Abbate,the medical director of the clinical research unit at VCU Medical Center, has to tell them about the possible benefits and risks.

But in the new reality where physical proximity means greater danger for health care workers and patients alike, hes had to get accustomed to having those conversations by video chat.

As of Friday, VCU had enrolled 38 people in trials to test two drugs,remdesivir andsarilumab.

Everybody stopped what they were doing and really focused on [COVID-19], said Dr. F. Gerard Moeller, who chairs the committee at VCU that reviews new clinical trials.

Studies on two experimental drugs were approved in days rather than the usual weeks or months it would usually take, he said.Currently, the trials are only for people whose COVID-19 is serious enough for them to be hospitalized and doctors determine which trial to enroll a patient based on the specifics of the case.

Were not jumping steps, were just working nights and weekends to make things happen, Abbate said, emphasizing the importance of not disregarding safety. I am optimistic that we will have treatments within months. Im just not sure which one it will be.

Remdesivir is an antiviral drug that has not been approved, but has been used experimentally to treat Ebola and tested in animals with other diseases caused by different kinds of coronaviruses. The company that manufactures the drug, Gilead Sciences Inc., announced hopeful results on April 10 that the drug had shown improvement in 68% of a small group of 53 patients with severe complications of COVID-19 treated through a clinical trial.

But the World Health Organization accidentally published findings from a trial that took place in China that found no benefit from the drug, but the findings were inconclusive because the study was ended early, Stat News reported Thursday. Remdesivir is also being tested at clinical trials at HCA Henrico Doctors Hospital and the University of Virginia Medical Center.

Sarilumab is approved for treating rheumatoid arthritis and is focused not on fighting the novel coronavirus directly, but on calming an overactive inflammatory response to the virus that damages the body.

At UVA Medical Center, doctors specializing in infectious disease and critical care began looking at evidence for different potential therapies for COVID-19 before treating their first patient.

We wanted to hit the ground running, said Dr. Patrick Jackson, an infectious disease specialist leading the remdesivir trial at UVA.

Jackson said that many of his patients have been enthusiastic about participating in the clinical trial because they want to be part of the effort to find a treatment for COVID-19 that will help more people down the road. Hes hoping to have some initial results from the trial, which is being run at hospitals across the country lead by the National Institutes of Health.

On Monday, his team will begin the second phase of the trial that will include adding a different drug, baricitinib, which is an anti-inflammatory used to treat rheumatoid arthritis.

They also plan to start enrolling patients in additional studies soon, including another effort to reduce the bodys inflammatory response by using adult stem cells.

Another experimental treatment that is taking hold across the world is the use of convalescent plasma, which is taken from the blood of people who have recovered from COVID-19. The plasma contains antibodies that can help the immune system fight of the virus.

Theres been a history of using the plasma of patients who have successfully recovered from a disease, said Dr. Dennis Szurkus, Chief Medical Officer at HCA Henrico Doctors Hospital, which is participating in a study run by the Mayo clinic. Were hoping it will be highly effective.

VCU Medical Center, Bon Secours hospitals and UVA Medical Center are also using the plasma treatment.

But in order for the hospitals to administer this treatment, they need blood donations from people who have recovered from COVID-19 and meet the criteria, which currently include having a positive test for the disease and being symptom free for at least 28 days, or symptom free for at least 14 days and have a negative COVID-19 test.

But as testing shortages have plagued the country, only 10% of the thousands of people who have reached out to the Red Cross hoping to donate over the last month met the eligibility criteria, according to a press release from the American Red Cross Friday.

To help streamline the process, last week, the Food and Drug Administration approved an antibody test that the Red Cross will roll out to screen donated plasma for COVID-19 antibodies. The Red Cross wont be doing antibody testing for the general public. Those wanting to donate can learn more at redcrossblood.org/plasma4covid.

But even as researchers talk about the promise of quickly moving toward potential treatments, theyre careful to warn against disregarding scientific protocol.

You want to do the best thing you can for that patient, said Moeller from VCUs clinical trial committee, explaining a physicians temptation to try out multiple treatments on a patient. At the same time, if you just throw everything at the patient without any evidence, you dont know if what you did helped the patient whether medications can be helpful or harmful without controlled studies, we dont know that.

The FDA has issued a warning against using hydroxychloroquine, an antimalarial drug that President Donald Trump has promoted as a possible treatment for COVID-19, outside of hospital and clinical trial settings because of possible side effects that could impact the heart.

Theres a pressure to get treatments out there -- as there should be, said Jackson, from UVA. But we also risk doing the wrong thing for patients We take very seriously the principal of, first, do no harm. Thats why clinical trials like this are so important.

View original post here:
There's no treatment for COVID-19, but Virginia researchers are ramping up clinical trials to try to find one - Richmond.com

Newest American Academy of Arts and Sciences members | Stanford News – Stanford University News

Fifteen Stanford faculty members are among the 276 new members elected to the American Academy of Arts and Sciences, which honors exceptional scholars, leaders, artists and innovators engaged in advancing the public good.

From left to right starting from the top: Howard Y. Chang, Arogyaswami J. Paulraj, Michele Barry, Dan Jurafsky, Eva Silverstein, Caroline M. Hoxby, Jenny S. Martinez, Guadalupe Valdes, Anne Joseph OConnell, Kenneth F. Scheve, Thomas A. Rando, Paul V. Kiparsky, Thomas R. Clandinin, James Ferguson and Florencia Torche. (Image credit: Andrew Brodhead)

The new Stanford members to join the Class of 2020 are as follows:

Michele Barry, the Drs. Ben & A. Jess Shenson Professor, is the senior associate dean for global health and director of the Center for Innovation in Global Health in the Stanford School of Medicine. She is also a professor of medicine, a senior fellow at the Woods Institute and at the Freeman Spogli Institute. As the co-founder and co-director of the Yale/Stanford Johnson and Johnson Global Health Scholar Award, she has sent more than 1,000 physicians overseas to underserved areas to help strengthen health infrastructure in low-resource settings.

Howard Y. Chang, the Virginia and D.K. Ludwig Professor of Cancer Genomics and of Genetics, is a professor of dermatology and of genetics. He is also a Howard Hughes Medical Institute investigator. Changs research focuses on the role of epigenomics in the control of large groups of genes involved in cell cycle control, and on the study of long noncoding RNAs in biological development, cancer and aging.

Thomas R. Clandinin, the Shooter Family Professor, is a professor and chair of neurobiology. Clandinins research focuses on three central questions in neurobiology: how neuronal circuits assemble during development, how the functions of these circuits are maintained during adult life and how these circuits mediate the complex computations essential to animal behavior.

James Ferguson, the Susan S. and William H. Hindle Professor in the School of Humanities and Sciences, is a professor of anthropology. His research has focused on southern Africa. His recent work has explored the surprising creation and/or expansion both in southern Africa and across the global South of social welfare programs that target the poor and are anchored in schemes that directly transfer small amounts of cash to large numbers of low-income people.

Caroline M. Hoxby, the Scott and Donya Bommer Professor in the School of Humanities and Sciences, is a professor of economics and a senior fellow at the Hoover Institution and at the Stanford Institute for Economic Policy Research (SIEPR). Hoxby specializes in public economics, the economics of education and labor economics.

Dan Jurafsky, the Jackson Eli Reynolds Professor in Humanities, is a professor of linguistics and computer science. His research ranges across computational linguistics, including natural language understanding, human conversation, the relationship between human and machine processing and the application of natural language processing to the social and behavioral sciences. He also works on the linguistics of food and the linguistics of Chinese.

Paul V. Kiparsky, the Robert M. and Anne T. Bass Professor in the School of Humanities and Sciences, is interested in how words are structured, how the vocabulary of a language is organized, how word meaning relates to syntax, how languages change, and what all this tells us about the human mind. His current work focuses on the interface between phonology and morphology.

Jenny S. Martinez, the Richard E. Lang Professor of Law, is dean of Stanford Law School. Martinez is an expert on international law and constitutional law, including comparative constitutional law. She is the author of The Slave Trade and the Origins of International Human Rights Law (Oxford University Press, 2012). An experienced litigator, she has worked on cases involving international law and constitutional law issues.

Anne Joseph OConnell, the Adelbert H. Sweet Professor of Law, is a lawyer and political scientist whose research and teaching focuses on administrative law and the federal bureaucracy. OConnell has written on such topics as agency and judicial nominations, political appointees, bureaucratic organization (and reorganization), political changes in agency rulemaking, quasi-agencies and congressional oversight of agencies.

Arogyaswami J. Paulraj is a professor (research) of electrical engineering, emeritus, and is the inventor of MIMO wireless communications, a technology that enables improved wireless performance. MIMO is now incorporated into all new wireless systems. He also pioneered MIMO-OFDMA technology, which has become the core of 4G mobile systems.

Thomas A. Rando, professor of neurology and neurological sciences, is the director of the Glenn Center for the Biology of Aging at Stanford and of the Rehabilitation Research and Development Center of Excellence at the Veterans Affairs Palo Alto Health Care System. His research focuses on understanding the biological signals that activate stem cells in response to injury or other environmental cues, particularly in the context of aging.

Kenneth F. Scheve is a professor of political science and a senior fellow at FSI. His research interests are in the fields of international and comparative political economy and comparative political behavior, with particular interest in the behavioral foundations of the politics of economic policymaking. He is currently examining the role of social preferences in opinion formation about tax policy, trade policy and international environmental cooperation. His work also focuses on the political origins of changes in wealth inequality in the 19th and 20th centuries.

Eva Silverstein, professor of physics, explores basic problems in several areas of theoretical physics, including mechanisms for cosmic inflation, supersymmetry breaking, the stabilization of extra dimensions in string theory and the physics of black holes. She is also a principal investigator on the Simons Foundation Origins of the Universe program.

Florencia Torche is a professor of sociology. Her research interests are in social demography, stratification and education. A longer-term area of her research examines inequality dynamics, with a particular focus on educational attainment, assortative mating and the intergenerational transmission of wealth.

Guadalupe Valdes, the Bonnie Katz Tenenbaum Professor of Education at Stanford Graduate School of Education, is a founding partner of Understanding Language, an initiative at Stanford that focuses attention on the role of language in subject-area learning. Her research explores many of the issues of bilingualism relevant to teachers in training and the role of education in national policies on immigration.

The American Academy of Arts and Sciences serves the nation as a champion of scholarship, civil dialogue and useful knowledge. The academy is committed to interdisciplinary, nonpartisan research that provides pragmatic solutions for complex challenges.

More here:
Newest American Academy of Arts and Sciences members | Stanford News - Stanford University News

Global trade impact of the Coronavirus Animal Stem Cell Therapy Market Size Overview, Top Companies, Inventive Trends and Forecast to 2032 – Germany…

Companies in the Animal Stem Cell Therapy market are vying suggestive steps to tackle the challenges resulting from the COVID-19 (Coronavirus) pandemic. Exhaustive research about COVID-19 is providing present-day techniques and alternative methods to mitigate the impact on Coronavirus on the revenue of the Animal Stem Cell Therapy market.

The report on the Animal Stem Cell Therapy market provides a birds eye view of the current proceedings and advancements within the Animal Stem Cell Therapy landscape. Further, the report ponders over the various factors that are likely to impact the overall dynamics of the Animal Stem Cell Therapy market over the forecast period (20XX-20XX) including the current trends, business expansion opportunities and restraining factors amongst others.

As per the market report suggested by ResearchMoz.us, the global Animal Stem Cell Therapy market is expected to register a CAGR growth of ~XX% during the forecast period and attain a value of ~US$XX by the end of 20XX. Further, the report suggests that the growth of the Animal Stem Cell Therapy market is largely influenced by a range of factors including, emphasis on R&D innovations by market players, surging investments to increase product portfolio, and favorable regulatory policies among others.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2638488&source=atm

Questions Related to the Animal Stem Cell Therapy Market Explained:

Competitive Landscape

The report provides critical insights related to the leading players operating in the Animal Stem Cell Therapy market. The revenue generated, market presence, product range, and financials of each company are enclosed in the report.

Segment by Type, the Animal Stem Cell Therapy market is segmented intoDogsHorsesOthers

Segment by Application, the Animal Stem Cell Therapy market is segmented intoVeterinary HospitalsResearch Organizations

Regional and Country-level AnalysisThe Animal Stem Cell Therapy market is analysed and market size information is provided by regions (countries).The key regions covered in the Animal Stem Cell Therapy market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.Competitive Landscape and Animal Stem Cell Therapy Market Share AnalysisAnimal Stem Cell Therapy market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Animal Stem Cell Therapy business, the date to enter into the Animal Stem Cell Therapy market, Animal Stem Cell Therapy product introduction, recent developments, etc.The major vendors covered:Medivet Biologics LLCVETSTEM BIOPHARMAJ-ARMU.S. Stem Cell, IncVetCell TherapeuticsCelavet Inc.Magellan Stem CellsKintaro Cells PowerAnimal Stem CareAnimal Cell TherapiesCell Therapy SciencesAnimacel

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2638488&source=atm

Regional Landscape

The regional landscape of the report provides resourceful insights related to the revenue share analysis of the Animal Stem Cell Therapy market in different regions. Further, the market attractiveness of each region provides players a clear understanding of the overall growth potential in each regional market.

End-User Analysis

The report provides an in-depth understanding of the various end-users of the Animal Stem Cell Therapy along with the market share, size, and revenue generated by each end-user.

Important Information that can be extracted from the Report:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2638488&licType=S&source=atm

Read the original post:
Global trade impact of the Coronavirus Animal Stem Cell Therapy Market Size Overview, Top Companies, Inventive Trends and Forecast to 2032 - Germany...

Coronavirus Doctors experiment with stem cell therapy on COVID-19 patients CBS News 9:39 AM – KTVQ Billings News

Doctors are hoping stem cell therapy could be a weapon in the fight against coronavirus. On Friday, regenerative medicine company Mesoblast announced a 300-person trial to determine whether stem cell treatments will work in COVID-19 patients suffering from severe lung inflammation.

One hospital in New York tried it as an experiment with 12 patients, 10 of whom were able to come off of ventilators.

"What we saw in the very first patient was that within four hours of getting the cells, a lot of her parameters started to get better," Dr. Karen Osman, who led the team at Mount Sinai, told CBS News' Adriana Diaz.

The doctor said she was encouraged by the results, though she was hesitant to link the stem cell procedure to her patients' recovery.

"We don't know" if the 10 people removed from ventilators would not have gotten had they not gotten the stem cells, she said. "And we would never dare to claim that it was related to the cells."

She explained that only a "randomized controlled trial" would be the only way "to make a true comparison."

Luis Naranjo, a 60-year-old COVID-19 survivor, was one of Mount Sinai's stem cell trial success stories. He told Diaz in Spanish that he was feeling "much better."

Naranjo's daughter, Paola, brought him to the emergency room, fearful she would not see her father again. Like so many families struck by the coronavirus, she was not allowed inside with him.

"I forgot to tell him that I love him," she said. "All I said was go inside, I hope you feel better."

During his hospital stay, Naranjo was unconscious and on a ventilator for 14 days.

Doctors proposed giving him stem cells from bone marrow in hopes it would suppress the severe lung inflammation caused by the virus.

Now, Naranjo credits the doctors who treated him for his survival. Though income from his family's jewelry business has been cut off and they found themselves falling behind on rent, Naranjo said he is focused primarily on his recovery and regaining the 25 pounds he lost at the hospital.

Although stem cell treatment, usually reserved for other diseases like rheumatoid arthritis, might end up being another step toward helping coronavirus patients recover, Dr. Osman was quick to say it would not be a "miracle treatment."

"The miracle treatment will be a vaccine," she said.

View post:
Coronavirus Doctors experiment with stem cell therapy on COVID-19 patients CBS News 9:39 AM - KTVQ Billings News

Call for ‘sofa life-savers’ as stem cell register takes a hit – Hereford Times

People have been urged to be a lifesaver from the sofa as a stem cell donor register has been adversely affected by the coronavirus crisis.

Charity DKMS said that the number of stem cell donor registrations is down by 50% compared with this time last year.

With operations and appointments being delayed, the need for donors will be much higher than usual in the months to come, it said.

The charity is encouraging people to register to become potential donors by sending swabs through the post.

People can sign up for a swab pack online, which will be posted out.

They then need to return the swabs in a pre-paid envelope which can be dropped to any local post box.

The family of a little girl with a rare blood cancer has backed the campaign.

Two-year-old Adeline Davidson, from Inverness, was diagnosed with myelodysplasia, a rare form of blood cancer, in February last year.

Her mother Steph Davidson, 26, said: We were so relieved when we heard that there was a match for Adeline, there were no words really this person who doesnt even know Adeline was giving her a second chance at life. It was the best news ever.

We were all ready for the transplant to start, but doctors took a throat swab from Adeline and found she had a common cold, so we had to wait a few days for that to clear up.

But in those few days the coronavirus situation completely blew up and we were told the transplant was no longer going to go ahead.

The transplant has been delayed for the foreseeable so we just have to wait and keep her healthy, because if she contracts any illness and has to be admitted to hospital, shes at high risk of infection.

She needs the transplant to live a normal life. We are a little fearful because of the delay and what this means for her future.

Were begging people to still register with DKMS if you can.

Jonathan Pearce, chief executive of DKMS UK, added: We are hugely concerned about the impact Covid-19 is having on those who rely on a blood stem cell donor.

While many stem cell transplants are still going ahead, the logistics around supporting blood stem cell donors to travel to hospital, and then arranging the transport of the stem cells to the transplant centre, have become much more challenging and complex.

There are also transplants that have been delayed, but once the pandemic is over we know there will be a backlog of patients in urgent need of an unrelated blood stem cell donor.

Sadly though, in some of those cases, theres a risk that the disease could progress further, and a transplant may no longer be possible once this is all over.

We still need many, many more potential blood stem cell donors to come forward, and we know from our clinicians that once the world is free of Covid-19, there will be even more transplants needed.

To find out more, visit https://www.dkms.org.uk/en/register-now

See the article here:
Call for 'sofa life-savers' as stem cell register takes a hit - Hereford Times

Insights on the Cell Expansion Industry in North America to 2027 – by Product, Cell Type, Application, End-user and Country – Yahoo Finance

Dublin, April 24, 2020 (GLOBE NEWSWIRE) -- The "North America Cell Expansion Market to 2027 - Regional Analysis and Forecasts by Product; Cell Type; Application; End User, and Country" report has been added to ResearchAndMarkets.com's offering.

The cell expansion market in North America is anticipated to reach USD 14,697.41 million by 2027 from USD 4,522.07 4 million in 2019; it is projected to grow at a CAGR of 15.9% during 2020-2027. The growth of the market is attributed to the increasing prevalence of cancer, rising number of new product launches, and increasing inclination of patients toward regenerative and personalized medicines. Also, growing R&D expenditure on cancer research is likely to have a positive impact on the growth of the market in the coming years. In addition, technological advancements in the pharmaceuticals industry and extensive developments in drug discovery are likely to stimulate the growth of cell expansion market in North America during the forecast period.

Cell expansion is the large-scale artificial production of daughter cells from a single cell, and the process is carried out to support the medical research. It plays a critical role in exploring a wider range of benefits and applications of fully differentiated stem cell cultures for their use in therapeutics, drug screening, or advanced research.

R&D is a significant part of a majority of pharmaceutical and biotech companies; they focus on R&D to come up with new molecules with the most significant medical and commercial potential for various therapeutic applications. The companies invest big amounts in these activities to deliver innovative, high-quality products to the market. Moreover, as per the report of Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expense of biopharmaceutical companies surged from US$ 49.6 billion in 2012 to US$ 58.8 billion in 2015.

Several government organizations are working on enhancing the detection methods and treatment procedures of cancer in the region. The National Cancer Institute (NCI) spends on various categories of the treatment, including specific cancer sites, cancer types, and cancer-related diseases, as well as types of NCI research mechanisms. The NCI allocated the funds of ~US$ 208.4 million for cell expansion research in 2017 from their total budget of US$ 5,636.4 million in that year for cancer research studies. Therefore, the growing R&D expenditure on cancer research by these companies is expected to provide them with opportunities for business expansion.

The North American cell expansion market has been segmented on the basis of cell type into human cells and animal cells. The human cells segment held a larger share of the market in 2018, and it is also projected to register a higher CAGR in it during the forecast period. Rise in research activities for the treatment of cancer is expected to offer considerable growth opportunities for the human cell expansion market players.

A few of the important secondary sources referred to for preparing this report on the cell expansion market are World Health Organization (WHO), Food and Drug Administration (FDA), Canadian Cancer Society, Centers for Disease Control and Prevention (CDC), and American Cancer Society.

Reasons to Buy:

Key Topics Covered:

1. Introduction1.1 Scope of the Study1.2 Report Guidance1.3 Market Segmentation1.3.1 North America Cell Expansion Market - By Product1.3.2 North America Cell Expansion Market - By Cell Type1.3.3 North America Cell Expansion Market - By Application1.3.4 North America Cell Expansion Market - By End User1.3.5 North America Cell Expansion Market - By Country

2. North America Cell Expansion Market- Key Takeaways

3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research

4. North America Cell Expansion Market - Market Landscape4.1 Overview4.2 PEST Analysis4.2.1 Cell Expansion Market - North America PEST Analysis4.3 Expert Opinion

5. North America Cell Expansion Market - Key Market Dynamics5.1 Key Market Drivers5.1.1 Patient shift towards regenerative medicines5.1.2 Increasing number of patients suffering with cancer5.2 Key Restraints5.2.1 Risk of contamination associated with the cell expansion process5.3 Key Market Opportunities5.3.1 Growing R&D Expenditure for Cancer Research5.4 Future Trend5.4.1 Extensive development in drug discovery5.5 Impact Analysis

6. Cell Expansion Market - North America Analysis6.1 North America Cell Expansion Market Revenue Forecasts and Analysis6.2 Positioning Of Key Players

7. North America Cell Expansion Market Analysis And Forecasts To 2027 - Product7.1 Overview7.2 North America Cell Expansion Market, By Product 2018 & 2027 (%)7.2.1 North America Cell Expansion Market Revenue and Forecasts to 2027, By Product (US$ Mn)7.2.1.1 North America Consumables Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.2.1.1.1 North America Disposables Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.2.1.2 North America Instruments Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.3 Consumables7.3.1 Overview7.3.2 North America Consumables Market Revenue and Forecast to 2027 (US$ Mn)7.3.3 Reagents, Media & Serum7.3.3.1 Overview7.3.3.2 North America Reagents, Media & Serum Market Revenue and Forecast to 2027 (US$ Mn)7.3.4 Disposables7.3.4.1 Overview7.3.4.2 North America Disposables Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.3 Culture Tissue Flasks7.3.4.3.1 Overview7.3.4.3.2 North America Culture Tissue Flasks Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.4 Bioreactor Accessories7.3.4.4.1 Overview7.3.4.4.2 North America Bioreactor Accessories Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.5 Other Disposables7.3.4.5.1 Overview7.3.4.5.2 North America Other Disposables Market Revenue and Forecast to 2027 (US$ Mn)7.4 Instruments7.4.1 Overview7.4.2 North America Instruments Market Revenue and Forecasts to 2027 (US$ Mn)7.4.3 Cell Expansion Supporting Equipment7.4.3.1 Overview7.4.3.2 North America Cell Expansion Supporting Equipment Market Revenue and Forecast to 2027 (US$ Mn)7.4.4 Bioreactors7.4.4.1 Overview7.4.4.2 North America Bioreactors Market Revenue and Forecast to 2027 (US$ Mn)7.4.5 Automated Cell Expansion Systems7.4.5.1 North America Automated Cell Expansion Systems Market Revenue and Forecast to 2027 (US$ Mn)

8. North America Cell Expansion Market Analysis And Forecasts To 2027 - Cell Type8.1 Overview8.2 North America Cell Expansion Market, By Cell Type 2018 & 2027 (%)8.2.1 North America Cell Expansion Market Revenue and Forecasts to 2027, By Cell Type (US$ Mn)8.3 Human Cells8.3.1 Overview8.3.2 North America Human Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.3 Adult Stem Cells8.3.3.1 Overview8.3.3.2 North America Adult Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.4 Induced Pluripotent Stem Cells8.3.4.1 Overview8.3.4.2 North America Induced Pluripotent Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.5 Embryonic Stem Cells8.3.5.1 Overview8.3.5.2 North America Embryonic Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.6 Differentiated Cells8.3.6.1 Overview8.3.6.2 North America Differentiated Cells Market Revenue and Forecast to 2027 (US$ Mn)8.4 Animal Cells8.4.1 Overview8.4.2 North America Animal Cells Market Revenue and Forecast to 2027 (US$ Mn)

9. North America Cell Expansion Market Analysis- By Application9.1 Overview9.2 North America Cell Expansion Market, By Application 2018 & 2027 (%)9.3 Regenerative Medicine and Stem Cell Research9.4 Cancer and Cell-based Research9.5 Other Applications

10. North America Cell Expansion Market Analysis- By End User10.1 Overview10.2 North America Cell Expansion Market, By End User 2018 & 2027 (%)10.3 Biopharmaceutical And Biotechnology Companies10.4 Research Institutes10.5 Cell Banks10.6 Other End Users

11. Cell Expansion Market Revenue And Forecasts To 2027 - Geographical Analysis11.1 North America Cell Expansion Market, Revenue and Forecast to 202711.1.1 North America Cell Expansion Market, Revenue and Forecast to 2027 (US$ Mn)11.1.2 North America Cell Expansion Market, Revenue and Forecast to 2027, By Product (US$ Mn)11.1.2.1 North America Consumables Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.2.1.1 North America Disposables Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.2.2 North America Instruments Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.3 North America Cell Expansion Market, Revenue and Forecast to 2027, By Cell Type (US$ Mn)11.1.3.1 North America Human Cell Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.4 North America Cell Expansion Market, Revenue and Forecast to 2027, By Application (US$ Mn)11.1.5 North America Cell Expansion Market, Revenue and Forecast to 2027, By End User (US$ Mn)11.1.6 North America Cell Expansion Market, Revenue and Forecast to 2027, By Country (%)11.1.7 US11.1.8 Canada11.1.9 Mexico

12. North America Cell Expansion Market- Industry Landscape12.1 Overview12.2 Growth Strategies In The Cell Expansion Market, 2017-201912.3 Organic Growth Strategies12.3.1 Overview12.3.1.1 Recent Organic Developments By Players In The Cell Expansion Market12.4 Inorganic Growth Strategies12.4.1 Overview12.4.2 Recent Developments By Players In The Cell Expansion Market

13. Global Cell Expansion Market-Key Company Profiles13.1 BD13.1.1 Key Facts13.1.2 Business Description13.1.3 Financial Overview13.1.4 Product Portfolio13.1.5 SWOT Analysis13.1.6 Key Developments13.2 Merck KGaA13.3 Thermo Fisher Scientific, Inc.13.4 Terumo Corporation13.5 General Electric Company13.6 Corning Incorporated13.7 Miltenyi Biotec13.8 Danaher13.9 Lonza13.10 STEMCELL Technologies, Inc.

14. Appendix14.1 About the Publisher14.2 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/gq37sj

Story continues

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See more here:
Insights on the Cell Expansion Industry in North America to 2027 - by Product, Cell Type, Application, End-user and Country - Yahoo Finance

UW-Madison: Academy adds new members from UW who ‘expand the boundaries of knowledge’ – Wisbusiness.com

MADISON Six University of Wisconsin-Madison faculty have been elected to the American Academy of Arts and Sciences.

Bioethicist R. Alta Charo, psychologist Seth Pollak, philosopher Steven Nadler, historian Louise Young, geographer Lisa Naughton and chemist Martin Zanni are among the 276 new members announced April 23. Election to the academy recognizes distinguished contributions by these scholars to their fields.

Former UW-Madison Provost Sarah Mangelsdorf was also elected to the academy this year. Mangelsdorf began her tenure as president of the University of Rochester in July 2019.

Charo is the Warren P. Knowles Professor of Law and Bioethics and an expert on law and policy related to research ethics, stem cell research and new medical technology. She has served as an adviser and expert to the federal government and multiple presidential administrations on ethical concerns in cutting-edge research. And she recently co-chaired a National Academy of Sciences panel to develop recommendations around human gene editing.

Pollak is the College of Letters & Science Distinguished Professor of Psychology. At UW-Madisons Waisman Center, he researches the link between childhood stress and well-being. Pollaks team has uncovered the lasting effects of negative experiences in childhood and seeks to use this knowledge to improve the social and emotional experiences of children and the adults they become.

Nadler is the William H. Hay II Professor and Evjue-Bascom Professor in Humanities and a philosopher specializing in early modern and Jewish philosophy. He has authored 13 books, including Rembrandts Jews, a Pulitzer Prize finalist, and the graphic book, co-authored with his son Ben Nadler, Heretics!: The Wondrous (and Dangerous) Beginnings of Modern Philosophy. Nadler currently serves as director of UW-Madisons Institute for Research in the Humanities.

Young is a professor of Japanese history. Her research has covered Japan in and around the Second World War, and she has authored two books on Japans culture before and during the war. Her current book projects include a history of the countrys transition from feudal systems to a modern class hierarchy and a reexamination of Japans role in creating the modern world from the mid-19th century onward.

Naughton is a professor of geography focused on the social and political consequences of biodiversity conservation. Her research has focused on protected areas, wildlife and land use conflicts in South America, and she has studied public attitudes toward wolf recovery in the Upper Midwest. She directed UW-Madisons Land Tenure Center from 2009 to 2013 and chaired the Nelson Institutes graduate program in Conservation Biology and Sustainable Development from 2007 to 2010.

Zanni is the V.W. Meloche-Bascom Professor of Chemistry. Using an innovative method known as two-dimensional spectroscopy, the Zanni lab studies topics in biophysics and the energy sciences. They have researched carbon nanotube energy transfer, solar cell charge transfer, and the ways in which protein aggregations lead to diseases such as Type 2 diabetes and cataracts. Zanni was elected a fellow of the American Physical Society in 2010.

The news that six colleagues are new members of the American Academy of Arts and Sciences is further evidence for a fact: Faculty at UW-Madison are extraordinary, says UW-Madison Provost Karl Scholz. We congratulate these six for this wonderful recognition and thank them, and all in the UW-Madison community, for relentless efforts to expand the boundaries of knowledge and understanding of the human condition.

The academy was formed in 1780 to honor exceptional individuals and engage them in advancing the public good. Members have included Benjamin Franklin, Alexander Hamilton, Margaret Mead and Martin Luther King Jr. This years new members include former Attorney General Eric Holder, author Ann Patchett and filmmaker Richard Linklater.

Read this article:
UW-Madison: Academy adds new members from UW who 'expand the boundaries of knowledge' - Wisbusiness.com

Potential Impact of COVID-19 on Induced Pluripotent Stem Cell Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 20582019-2019 – Jewish Life…

In 2018, the market size of Induced Pluripotent Stem Cell Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Induced Pluripotent Stem Cell market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Induced Pluripotent Stem Cell market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Induced Pluripotent Stem Cell market to assist our clients arrive at beneficial business decisions.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/17968

This study presents the Induced Pluripotent Stem Cell Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Induced Pluripotent Stem Cell history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global Induced Pluripotent Stem Cell market, the following companies are covered:

Company Profile

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/17968

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Induced Pluripotent Stem Cell product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Induced Pluripotent Stem Cell, with price, sales, revenue and global market share of Induced Pluripotent Stem Cell in 2017 and 2018.

Chapter 3, the Induced Pluripotent Stem Cell competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Induced Pluripotent Stem Cell breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/17968

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Induced Pluripotent Stem Cell market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Induced Pluripotent Stem Cell sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Read more here:
Potential Impact of COVID-19 on Induced Pluripotent Stem Cell Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 20582019-2019 - Jewish Life...